Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis

Allergologia et Immunopathologia

Volumn 43, Issue 3, 2015, Pages 298-303

  Sanchez Solis M ^a   Gartner, S ^b   Bosch Gimenez, V ^a   Garcia Marcos, L ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Admission rate; Bronchiolitis; Cystic fibrosis; Palivizumab; Prophylaxis; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT;

ARTICLE; CLINICAL EFFECTIVENESS; CYSTIC FIBROSIS; HOSPITAL ADMISSION; HUMAN; INFECTION PREVENTION; META ANALYSIS; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; ANIMAL; COMPLICATION; HOSPITALIZATION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

ANIMALS; ANTIVIRAL AGENTS; CYSTIC FIBROSIS; HOSPITALIZATION; HUMANS; PALIVIZUMAB; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 84929288866     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1016/j.aller.2013.09.003     Document Type: Article

References (23)

1. Abman S.H., Ogle J.W., Butler-Simon N., Rumack C.M., Accurso F.J. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 1988, 113:826-830.
2. Hiatt P.W., Grace S.C., Kozinetz C.A., Raboudi S.H., Treece D.G., Taber L.H., et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999, 103:619-626.
3. Arnold S.R., Wang E.E., Law B.J., Boucher F.D., Stephens D., Robinson J.L., et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database pediatric investigators collaborative network on infections in Canada. Pediatr Infect Dis J 1999, 18:866-869.
4. Petersen N.T., Hoiby N., Mordhorst C.H., Lind K., Flensborg E.W., Bruun B. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma - possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand 1981, 70:623-628.
5. Collinson J., Nicholson K.G., Cancio E., Ashman J., Ireland D.C., Hammersley V., et al. Effects of upper respiratory tract infections in patients with cystic fibrosis. Thorax 1996, 51:1115-1122.
6. Armstrong D., Grimwood K., Carlin J.B., Carzino R., Hull J., Olinsky A., et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol 1998, 26:371-379.
7. Van Ewijk B.E., Wolfs T.F., Aerts P.C., Van Kessel K.P., Fleer A., Kimpen J.L., et al. RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res 2007, 61:398-403.
8. de Vrankrijker A.M., Wolfs T.F., Ciofu O., Hoiby N., Van der Ent C.K., Poulsen S.S., et al. Respiratory syncytial virus infection facilitates acute colonization of Pseudomonas aeruginosa in mice. J Med Virol 2009, 81:2096-2103.
9. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998, 102:531-537.
10. Feltes T.F., Cabalka A.K., Meissner H.C., Piazza F.M., Carlin D.A., Top F.H., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003, 143:532-540.
11. Cohen A.H., Boron M.L., Dingivan C. A phase IV study of the safety of SynagisTM (Palivizumab) for prophilaxis of respiratory syncytial virus. Proc Am Thorac Soc 2005, 2:A189.
12. Robinson K.A., Odelola O.A., Saldanha I., McKoy N. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 2010, 2:CD007743.
13. Robinson K.A., Odelola O.A., Saldanha I.J., McKoy N.A. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 2012, 2:CD007743.
14. Robinson K.A., Odelola O.A., Saldanha I.J., McKoy N.A. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 2013, 6:CD007743.
15. McCormick J., Southern K.W. A survey of palivizumab for infants with cystic fibrosis in the UK. Arch Dis Child 2007, 92:87-88.
16. Hampp C., Saidi A.S., Winterstein A.G. Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida. J Pediatr 2010, 156:953-959.
17. Giusti R. North American synagis prophylaxis survey. Pediatr Pulmonol 2009, 44:96-98.
18. Giebels K., Marcotte J.E., Podoba J., Rousseau C., Denis M.H., Fauvel V., et al. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol 2008, 43:169-174.
19. Sorrentino M., Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr Infect Dis J 2000, 19:1068-1071.
20. Speer M.E., Fernandes C.J., Boron M., Groothuis J.R. Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. Pediatr Infect Dis J 2008, 27:559-561.
21. Paes B., Mitchell I., Li A., Lanctot K.L. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr 2012, 171:833-841.
22. Kristensen K., Hjuler T., Ravn H., Simoes E.A., Stensballe L.G. Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study. Clin Infect Dis 2012, 54:810-817.
23. Winterstein A.G., Eworuke E., Xu D., Schuler P. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis. Pediatr Pulmonol 2012, 10.1002/ppul.22711.